GKOS
VENTE TOTALE: 3 025 titres (~563 005,75 $ US)
- Insiders
- Kliman Gilbert H, WEN LEANA
- Total bought
- —
- Total sold
- $563,006
- Last activity
- 2026-08-19
- Last synced
-
2026-08-25 17:08:49
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Neutral signal Scored 2026-09-06
GKOS presents a compelling earnings catalyst with 50% revenue growth, raised guidance, and strong market momentum (YTD +67%), supported by solid liquidity (score: 75).
The first sentence of the analysis written for GKOS on 2026-09-06 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 77.5% | 75.5% | 76.0% | 75.6% | 77.3% | |
| Ebit Margin | -37.1% | -35.4% | -38.2% | -29.9% | -12.2% | |
| Ebitda Margin | -28.8% | -24.9% | -26.1% | -17.2% | -0.5% | |
| Operating Profit Margin | -17.1% | -31.9% | -40.9% | -29.1% | -11.2% | |
| Pretax Profit Margin | -38.0% | -38.0% | -42.5% | -34.8% | -16.8% | |
| Continuous Operations Profit Margin | -37.0% | -38.2% | -42.8% | -35.1% | -16.9% | |
| Net Profit Margin | -37.0% | -38.2% | -42.8% | -35.1% | -16.9% | |
| Bottom Line Profit Margin | -37.0% | -38.2% | -42.8% | -35.1% | -16.9% | |
| Current Ratio | 4.690 | 5.987 | 5.343 | 6.134 | 7.672 | |
| Quick Ratio | 4.062 | 5.219 | 4.776 | 5.611 | 7.309 | |
| Solvency Ratio | -0.612 | -0.512 | -0.202 | -0.116 | -0.028 | |
| Cash Ratio | 0.897 | 2.258 | 1.263 | 1.652 | 1.589 | |
| Price To Earnings Ratio | -34.424 | -54.130 | -28.594 | -20.900 | -41.533 | |
| Price To Earnings Growth Ratio | -1.870 | 150.481 | -0.866 | -0.219 | 0.688 | |
| Forward Price To Earnings Growth Ratio | -1.870 | 150.481 | -0.866 | -0.219 | 0.688 | |
| Price To Earnings Diluted Ratio | -34.424 | -54.130 | -28.594 | -20.900 | -41.533 | |
| Price To Earnings Diluted Growth Ratio | -1.870 | 150.481 | -0.866 | -0.219 | 0.688 | |
| Price To Book Ratio | 9.841 | 10.314 | 8.337 | 3.910 | 3.514 | |
| Price To Sales Ratio | 12.725 | 20.627 | 12.233 | 7.326 | 7.017 | |
| Price To Free Cash Flow Ratio | -119.567 | -116.982 | -49.354 | -32.714 | -89.398 | |
| Price To Operating Cash Flow Ratio | -139.347 | -129.001 | -66.656 | -62.641 | 83.497 | |
| Debt To Assets Ratio | 0.156 | 0.106 | 0.408 | 0.356 | 0.340 | |
| Debt To Equity Ratio | 0.213 | 0.135 | 0.831 | 0.722 | 0.653 | |
| Debt To Capital Ratio | 0.175 | 0.119 | 0.454 | 0.419 | 0.395 | |
| Long Term Debt To Capital Ratio | 0.052 | 0.000 | 0.380 | 0.347 | 0.323 | |
| Financial Leverage Ratio | 1.362 | 1.271 | 2.037 | 2.027 | 1.923 | |
| Working Capital Turnover Ratio | 1.356 | 1.102 | 0.908 | 0.712 | 0.698 | |
| Operating Cash Flow Ratio | -0.458 | -0.816 | -0.780 | -0.457 | 0.390 | |
| Operating Cash Flow Sales Ratio | -0.091 | -0.160 | -0.184 | -0.117 | 0.084 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.165 | 1.103 | 1.351 | 1.915 | -0.934 | |
| Debt Service Coverage Ratio | -30.358 | -9.603 | -6.092 | -3.500 | -0.125 | |
| Interest Coverage Ratio | -18.713 | -12.188 | -9.440 | -5.999 | -2.458 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | -76.937 | 24.463 | |
| Operating Cash Flow Coverage Ratio | -0.332 | -0.593 | -0.151 | -0.086 | 0.064 | |
| Capital Expenditure Coverage Ratio | -6.045 | -9.733 | -2.853 | -1.093 | 0.517 | |
| Dividend Paid And Capex Coverage Ratio | -6.045 | -9.733 | -2.853 | -1.093 | 0.517 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -44.544 | -82.015 | -50.419 | -47.900 | -1,591.394 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 77.5% | ▲2.0% | ▲1.1% |
| Ebit Margin | -37.1% | ▼-1.8% | ▼-6.6% |
| Ebitda Margin | -28.8% | ▼-3.8% | ▼-9.3% |
| Operating Profit Margin | -17.1% | ▲14.8% | ▲8.9% |
| Pretax Profit Margin | -38.0% | ▼-0.1% | ▼-4.0% |
| Continuous Operations Profit Margin | -37.0% | ▲1.2% | ▼-3.0% |
| Net Profit Margin | -37.0% | ▲1.2% | ▼-3.0% |
| Bottom Line Profit Margin | -37.0% | ▲1.2% | ▼-3.0% |
| Current Ratio | 4.690 | ▼-1.297 | ▼-1.275 |
| Quick Ratio | 4.062 | ▼-1.157 | ▼-1.333 |
| Solvency Ratio | -0.612 | ▼-0.100 | ▼-0.318 |
| Cash Ratio | 0.897 | ▼-1.361 | ▼-0.635 |
| Price To Earnings Ratio | -34.424 | ▲19.706 | ▲1.492 |
| Price To Earnings Growth Ratio | -1.870 | ▼-152.351 | ▼-31.512 |
| Forward Price To Earnings Growth Ratio | -1.870 | ▼-152.351 | ▼-31.512 |
| Price To Earnings Diluted Ratio | -34.424 | ▲19.706 | ▲1.492 |
| Price To Earnings Diluted Growth Ratio | -1.870 | ▼-152.351 | ▼-31.512 |
| Price To Book Ratio | 9.841 | ▼-0.473 | ▲2.658 |
| Price To Sales Ratio | 12.725 | ▼-7.902 | ▲0.740 |
| Price To Free Cash Flow Ratio | -119.567 | ▼-2.585 | ▼-37.964 |
| Price To Operating Cash Flow Ratio | -139.347 | ▼-10.346 | ▼-76.517 |
| Debt To Assets Ratio | 0.156 | ▲0.050 | ▼-0.117 |
| Debt To Equity Ratio | 0.213 | ▲0.078 | ▼-0.298 |
| Debt To Capital Ratio | 0.175 | ▲0.057 | ▼-0.137 |
| Long Term Debt To Capital Ratio | 0.052 | ▲0.052 | ▼-0.169 |
| Financial Leverage Ratio | 1.362 | ▲0.091 | ▼-0.362 |
| Working Capital Turnover Ratio | 1.356 | ▲0.254 | ▲0.401 |
| Operating Cash Flow Ratio | -0.458 | ▲0.359 | ▼-0.033 |
| Operating Cash Flow Sales Ratio | -0.091 | ▲0.069 | ▲0.002 |
| Free Cash Flow Operating Cash Flow Ratio | 1.165 | ▲0.063 | ▲0.245 |
| Debt Service Coverage Ratio | -30.358 | ▼-20.756 | ▼-20.423 |
| Interest Coverage Ratio | -18.713 | ▼-6.525 | ▼-8.953 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | ▲10.495 |
| Operating Cash Flow Coverage Ratio | -0.332 | ▲0.261 | ▼-0.112 |
| Capital Expenditure Coverage Ratio | -6.045 | ▲3.688 | ▼-2.204 |
| Dividend Paid And Capex Coverage Ratio | -6.045 | ▲3.688 | ▼-2.204 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -44.544 | ▲37.471 | ▲318.711 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $6.46B | $7.91B | $3.85B | $2.07B | $2.06B | |
| Enterprise value | $6.51B | $7.84B | $4.14B | $2.34B | $2.35B | |
| EV / Sales | 12.82x | 20.45x | 13.16x | 8.26x | 7.98x | |
| EV / Op. cash flow | -140.40x | -127.92x | -71.68x | -70.60x | 94.94x | |
| EV / Free cash flow | -120.47x | -116.00x | -53.08x | -36.87x | -101.65x | |
| EV / EBITDA | -44.54x | -82.02x | -50.42x | -47.90x | -1591.39x | |
| Net debt / EBITDA | -0.33x | 0.69x | -3.54x | -5.40x | -191.78x | |
| Current ratio | 4.69x | 5.99x | 5.34x | 6.13x | 7.67x | |
| Income quality | 0.35x | 0.42x | 0.43x | 0.33x | -0.50x | |
| Graham net-net | $3 | $4 | -$3 | -$3 | -$2 | |
| Tax burden | 97.2% | 100.5% | 100.7% | 100.8% | 100.7% | |
| Interest burden | 102.5% | 107.4% | 111.4% | 116.2% | 137.3% | |
| Working capital | $373.7M | $374.7M | $321.4M | $371.5M | $422.8M | |
| Invested capital | $766.5M | $874.2M | $845.1M | $912.3M | $967.8M | |
| Return on assets | -21.0% | -15.0% | -14.3% | -9.2% | -4.4% | |
| Operating ROA | -9.3% | -12.8% | -12.8% | -7.5% | -3.1% | |
| Return on tangible assets | -27.4% | -22.7% | -22.8% | -14.2% | -6.8% | |
| Return on equity | -28.6% | -19.1% | -29.2% | -18.7% | -8.4% | |
| Return on invested capital | -10.6% | -13.6% | -14.9% | -8.2% | -3.1% | |
| Return on capital employed | -10.9% | -13.6% | -14.9% | -8.2% | -3.1% | |
| Earnings yield | -2.9% | -1.9% | -3.5% | -4.8% | -2.4% | |
| Free cash flow yield | -0.8% | -0.9% | -2.0% | -3.1% | -1.1% | |
| Capex / Op. cash flow | -16.5% | -10.3% | -35.1% | -91.5% | 193.4% | |
| Capex / Depreciation | 20.1% | 15.8% | 53.3% | 84.2% | 138.8% | |
| Capex / Sales | 1.5% | 1.6% | 6.4% | 10.7% | 16.3% | |
| SG&A / Sales | 64.9% | 68.5% | 71.2% | 68.2% | 61.0% | |
| R&D / Sales | 29.7% | 35.6% | 44.1% | 43.6% | 34.4% | |
| Stock comp / Sales | 12.5% | 13.1% | 13.8% | 13.6% | 10.3% | |
| Intangibles / Total assets | 23.3% | 33.8% | 37.1% | 34.8% | 35.3% | |
| Days sales outstanding | 78d | 58d | 46d | 47d | 42d | |
| Days payables outstanding | 79d | 51d | 65d | 76d | 40d | |
| Operating cycle | 281d | 282d | 249d | 247d | 168d | |
| Cash conversion cycle | 203d | 231d | 184d | 171d | 127d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▼-18.4%EV / Sales ▼-37.3%EV / EBITDA ▲+45.7%EV / Op. cash flow ▼-12.479Earnings yield ▼-0.011
Profitability
Return on equity ▼-0.095Return on assets ▼-0.060Return on invested capital ▲+0.030Return on capital employed ▲+0.027Operating ROA ▲+0.035Income quality ▼-0.072Tax burden ▼-0.033
Efficiency
Days sales outstanding ▲+20.305Days payables outstanding ▲+28.119Operating cycle ▼-0.480Cash conversion cycle ▼-28.599Capex / Sales ▼-0.001R&D / Sales ▼-0.059
Balance-sheet strength
Current ratio ▼-1.297Net debt / EBITDA ▼-1.027Working capital ▼-958000.000Invested capital ▼-107664000.000Intangibles / Total assets ▼-0.105
Change over 5 years
Valuation
Market cap ▲+213.0%EV / Sales ▲+60.7%EV / EBITDA ▲+97.2%EV / Op. cash flow ▼-235.338Earnings yield ▼-0.005
Profitability
Return on equity ▼-0.202Return on assets ▼-0.166Return on invested capital ▼-0.076Return on capital employed ▼-0.079Operating ROA ▼-0.062Income quality ▲+0.845Tax burden ▼-0.034
Efficiency
Days sales outstanding ▲+36.609Days payables outstanding ▲+38.512Operating cycle ▲+113.663Cash conversion cycle ▲+75.151Capex / Sales ▼-0.147R&D / Sales ▼-0.047
Balance-sheet strength
Current ratio ▼-2.982Net debt / EBITDA ▲+191.441Working capital ▼-49057000.000Invested capital ▼-201295000.000Intangibles / Total assets ▼-0.120
Employee count
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-08-24 61,957 Shares in Glaukos Corporation $GKOS Purchased by Deutsche Bank AG Deutsche Bank AG acquired a new stake in Glaukos Corporation (NYSE: GKOS) during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 61,957 shares of the medical instruments supplier''s stock, valued at approximately $8,659,000. Deutsche Bank AG owned about 0.11% of Glaukos at the
- 2026-08-20 GKOS Stock Surges 67% Year to Date: What''s Driving the Rally? Glaukos'' iDose TR momentum and Epioxa launch are driving record growth, higher 2026 guidance and a broader ophthalmology platform.
- 2026-08-19 Here''s Why You Should Retain Glaukos Stock in Your Portfolio for Now Glaukos'' iDose TR and Epioxa are driving rapid growth, while margin expansion and a broad pipeline strengthen its long-term prospects.
- 2026-08-19 Glaukos Announces Participation in Wells Fargo Healthcare Conference ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced that its management is scheduled to participate in the Wells Fargo Healthcare Conference on Wednesday, September 9, 2026, at 3:00 p.m. ET in Boston, MA. A live and archived webcast for these events, where applicable, will be available in the Investors.
- 2026-08-13 Which Small-Cap ETF Is the Better Buy: iShares'' Growth-Focused IWO or Invesco''s Revenue-Weighted RWJ? Small-cap stocks are surging, but how you own them matters more than most investors realize.
- 2026-08-05 First Trust Advisors LP Acquires 40,798 Shares of Glaukos Corporation $GKOS First Trust Advisors LP increased its holdings in Glaukos Corporation (NYSE: GKOS) by 2,085.8% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 42,754 shares of the medical instruments supplier''s stock after buying an additional 40,798 shares
- 2026-07-30 Glaukos Q2 Earnings Beat Estimates on iDose TR Growth, Stock Up GKOS'' Q2 loss narrows as revenues jump 50% on iDose TR and Epioxa growth, lifting its 2026 sales outlook and shares by 9.8%.
- 2026-07-30 Glaukos Q2 Earnings Call Highlights Glaukos NYSE: GKOS reported record second-quarter 2026 consolidated net sales of $185.6 million, up 50% from the prior-year period on a reported basis and 49% on a constant-currency basis, as growth in its U.S. glaucoma, international glaucoma and corneal health businesses exceeded management''s expectations.
- 2026-07-29 Glaukos (GKOS) Reports Q2 Earnings: What Key Metrics Have to Say Although the revenue and EPS for Glaukos (GKOS) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
- 2026-07-29 Glaukos Corporation (GKOS) Q2 2026 Earnings Call Transcript Glaukos Corporation (GKOS) Q2 2026 Earnings Call Transcript